Results 111 to 120 of about 6,800,049 (185)

Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1083-1096, October 2026.
In the POISE open‐label extension, patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid received long‐term obeticholic acid (OCA) treatment. Findings demonstrated a safety profile consistent with the known characteristics of OCA, with no unexpected safety signals, while supporting sustained efficacy ...
Christopher L. Bowlus, Frederik Nevens, Kris V. Kowdley, Alan Bonder, Thomas Capozza, Jing Li, Radhika Nair, Michael Trauner, David E. Jones   +8 more
wiley   +1 more source

Lipid Accumulation Promotes Tumorigenic Behaviour of Colorectal Cancer Cells

Journal of Cellular and Molecular Medicine, Volume 30, Issue 19, October 2026.
ABSTRACT Obesity and hyperlipidemia are risk factors for the development and progression of different types of cancer including colorectal cancer (CRC). The underlying mechanisms are only incompletely understood. The aim of this study was to assess the impact of hyperlipidemic conditions on tumorigenic behaviour of CRC cells and the effect of obesity ...
Tatjana Itzenhäuser, Fulya Suzan Schildt, Seraphine Jochem, Judith Sommer, Michael Stürzl, Elisabeth Naschberger, Anja Katrin Boßerhoff, Claus Hellerbrand   +7 more
wiley   +1 more source

Bile Acid Metabolism as a Unifying Readout for Diet, Microbiome Function, and Gastrointestinal Disease

The FASEB Journal, Volume 40, Issue 17, 15 September 2026.
Dietary components shape the gut microbiome, which modifies bile acids through transformations. The resulting bile acid pool is sensed by host receptors to regulate immunity, metabolism, and intestinal function. Targeted bile acid measurements provide a unifying readout to study diet‐microbiome interactions and to develop next‐generation dietary ...
Jason Dichter
wiley   +1 more source

A Novel SXXLF Motif in the FXR N‐Terminal Domain Mediates Coregulator and Interdomain Interactions

ChemBioChem, Volume 27, Issue 17, 14 September 2026.
Farnesoid X receptor (FXR)‐N‐terminal domain (NTD) regulates transcriptional activity through interdomain communication with the LBD and is also involved in co‐activator recruitment. The SENLF motif is the first defined functional element within the FXR‐NTD and mediates both NTD–LBD interaction and selective co‐activator engagements to drive NTD ...
Priscilla Villalona, Thilini Pulahinge, Tracy Yu, Jordan Wenning, Sabab Hasan Khan, Crawford Joseph Frisbie, Jill Magafas, Addison Barbe, C. Denise Okafor   +8 more
wiley   +1 more source

Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning.

, 2019
Invited for this month's cover picture is the group of Prof. Dr. Gisbert Schneider from the Swiss Federal Institute of Technology (ETH) Zurich (Switzerland). The cover picture illustrates the application of machine-learning methods to expand the chemical
Schneider G, Grisoni F, Friedrich L, Schaller K, Merk D   +4 more
core   +1 more source

Farnesoid X receptor: from structure to potential clinical applications.

, 2005
The farnesoid X receptor (FXR) is a well-characterized member of the “metabolic” subfamily of NRs. In 1999 FXR was recognized to be a transcriptional sensor for bile acids which are therefore witnessing their “renaissance” as signaling molecules ...
FIORUCCI S., COSTANTINO, Gabriele, PELLICCIARI R   +2 more
core   +1 more source

Clinical significance of farnesoid X receptor expression in thyroid neoplasia

, 2017
Aim: To evaluate the clinical significance of farnesoid X receptor (FXR) in thyroid neoplasia. Patients & methods: FXR expression was assessed immunohistochemically on 88 thyroid neoplastic tissues (benign = 44, malignant = 44).
Efstratios Patsouris, Nikolaos Tsoukalas, Gerasimos Tsourouflis, Eugene Dana, Paraskevi Alexandrou, Stamatios Theocharis, Ioanna Delladetsima, Constantinos Giaginis   +7 more
core   +1 more source

Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists

, 2017
Farnesoid X receptor (FXR), a nuclear receptor mainly distributed in liver and intestine, has been regarded as a potential target for the treatment of various metabolic diseases, cancer and infectious diseases related to liver.
Shuainan Liu, Xing Wang, Chen, Yuan, Na Wang, Huan, Yi, Qian Jiang, Yuan Chen, Verma, Ruchi, Xu, Yang, Fang, Weishuo, Jinsong Liu, Liu, Shuainan, Chiwai Wong, Yi Huan, Liu, Jinsong, Ruitang Deng, Wong, Chiwai, Zhang, Guoning, Zhang, Yanqiao, Zhufang Shen, Wang, Na, Ruchi Verma, Tan, Wenjuan, Sun, Deyang, Shen, Zhufang, Wang, Xing, Wenjuan Tan, Deyang Sun, Yang Xu, Weishuo Fang, Guoning Zhang, Yanqiao Zhang, Jiang, Qian, Deng, Ruitang   +33 more
core   +1 more source

The farnesoid X receptor: a novel drug target?

, 2004
Bile acids are end products of cholesterol metabolism. They are exclusively synthesised by the liver and subsequently secreted via the bile duct into the intestine to facilitate the absorption of dietary fat and fat-soluble vitamins.
Kuipers, F; id_orcid, Sturm, E, Staels, B, Kuipers, F, Claudel, T   +4 more
core  

Chenodeoxycholic acid suppresses colorectal cancer by activating Farnesoid X receptor. [PDF]

Am J Cancer Res
Xie J, He Y, Xu C, Wang S, Qu G, Ren Y, Wang T, Xue Y.   +7 more
europepmc   +1 more source